Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis.

Sublingual apomorphine could be an option in patients with erectile dysfunction who cannot take phosphodiesterase type 5 inhibitors (e.g., using nitrates). We have completed a systematic review to evaluate the effects of sublingual apomorphine comparing with placebo for treating erectile dysfunction...

Descripción completa

Detalles Bibliográficos
Publicado en:Archives of Sexual Behavior Vol. 49; no. 8; pp. 2963 - 2980
Autores principales: Guillén, Virginia, Rueda, José-Ramón, Lopez-Argumedo, Marta, Solà, Ivan, Ballesteros, Javier
Formato: Artículo
Publicado: Springer Nature Nov2020
Materias:
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=146832873&site=ehost-live
header:
  @attributes:
    shortDbName: ssf
    uiTerm: 146832873
    longDbName: Social Sciences Full Text (H.W. Wilson)
    uiTag: AN
  controlInfo:
    bkinfo:
    jinfo:
      jid:
        00040002
        ASX
      jtl: Archives of Sexual Behavior
      issn: 00040002
      maglogo: N
    pubinfo:
      dt: Nov2020
      vid: 49
      iid: 8
      pid: 237
      pub: Springer Nature
    artinfo:
      ui:
        146832873
        10.1007/s10508-020-01817-5
      ppf: 2963
      ppct: 17
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
              size: 727KB
      tig:
        atl: Apomorphine for the Treatment of Erectile Dysfunction: Systematic Review and Meta-Analysis.
      aug:
        au:
          Guillén, Virginia
          Rueda, José-Ramón
          Lopez-Argumedo, Marta
          Solà, Ivan
          Ballesteros, Javier
        affil:
          Department of Neuroscience, Faculty of Medicine and Nursing, University of the Basque Country, Leioa, Spain
          Department of Preventive Medicine and Public Health, Faculty of Medicine and Nursing, University of the Basque Country, 48080, Leioa, Spain
          Department of Health, Osteba, Basque Office for Health Technology Assessment, Vitoria-Gasteiz, Spain
          Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau, CIBER Epidemiología y Salud Pública, Universitat Autònoma de Barcelona, Barcelona, Spain
          CIBER Salud Mental, Madrid, Spain
      su:
        Sexual intercourse
        Placebos
        Randomized controlled trials
        Apomorphine
        Impotence
        Meta-analysis
      sug:
        subj:
          Sexual intercourse
          Placebos
          Randomized controlled trials
          Apomorphine
          Impotence
          Meta-analysis
      keyword:
        DSM-5
        Erectile dysfunction
        Randomized controlled trial (RCT)
        DSM-5
        Erectile dysfunction
        Randomized controlled trial (RCT)
      ab: Sublingual apomorphine could be an option in patients with erectile dysfunction who cannot take phosphodiesterase type 5 inhibitors (e.g., using nitrates). We have completed a systematic review to evaluate the effects of sublingual apomorphine comparing with placebo for treating erectile dysfunction. The evidence searching process finished on 9 January 2019. We included nine randomized controlled trials (RCTs). Treatment length varied from 4 to 8 weeks and doses ranged from 2 to 6 mg. The percent of successful sexual intercourse attempts per ingested dose of apomorphine was evaluated in eight studies. All the studies found that apomorphine was better than placebo (6–27% more successful intercourse attempts than with placebo), but differences were not statistically significant in one study done in patients previously treated with radical prostatectomy. Regarding erectile function scores, three studies reported higher improvement on the erectile function scores for apomorphine. Differences with placebo were not clinically relevant in another two studies, one in which only diabetic patients were included and one in which only patients with radical prostatectomy were involved. Discontinuation of treatment due to adverse events was higher for apomorphine, particularly for higher doses. Available evidence suggests that sublingual apomorphine is more effective than placebo, except for patients previously treated with radical prostatectomy, and is generally well tolerated at doses of 2 or 3 mg. Nowadays, sublingual apomorphine is the only licensed oral drug for erectile dysfunction not absolutely contraindicated with nitrates use, and more RCTs should be performed to evaluate its effects and safety for treating ED.
      pubtype: Academic Journal
      doctype: Article
      src: R
    language: English
    refInfo:
    copyright:
      @attributes:
        flag: N
    holdings:
      @attributes:
        islocal: N